- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 2.11 Å
- Oligo State
- monomer
- Ligands
- 1 x 7MA: N-ethyl-2-[(6-methoxypyridin-3-yl)-(2-methylphenyl)sulfonyl-amino]-N-(pyridin-3-ylmethyl)ethanamide(Non-covalent)
- 2 x SO4: SULFATE ION(Non-functional Binders)
SO4.2: 4 residues within 4Å:- Chain A: K.239, S.306, G.307, K.308
4 PLIP interactions:4 interactions with chain A- Hydrogen bonds: A:G.307, A:K.308
- Water bridges: A:K.239
- Salt bridges: A:K.239
SO4.3: 4 residues within 4Å:- Chain A: R.120, A.123, Q.233, R.237
3 PLIP interactions:3 interactions with chain A- Hydrogen bonds: A:Q.233
- Salt bridges: A:R.120, A:R.237
- 2 x PG4: TETRAETHYLENE GLYCOL(Non-functional Binders)
PG4.4: 7 residues within 4Å:- Chain A: K.265, R.266, F.271, R.272, V.280, Y.281, F.284
3 PLIP interactions:3 interactions with chain A- Hydrogen bonds: A:R.272
- Water bridges: A:D.179, A:R.266
PG4.5: 8 residues within 4Å:- Chain A: L.204, A.208, Y.211, F.215, M.245, V.248, A.252
- Ligands: SOG.12
No protein-ligand interaction detected (PLIP)- 25 x SOG: octyl 1-thio-beta-D-glucopyranoside(Non-covalent)(Non-functional Binders)
SOG.6: 7 residues within 4Å:- Chain A: K.189, S.193, V.267, F.268, G.269
- Ligands: SOG.29, SOG.30
Ligand excluded by PLIPSOG.7: 10 residues within 4Å:- Chain A: W.12, Y.17, Y.21, V.24, D.83, E.86, Y.281, A.282, T.285
- Ligands: SOG.8
Ligand excluded by PLIPSOG.8: 10 residues within 4Å:- Chain A: R.13, Y.17, P.18, A.22, W.23, I.84, T.85, E.86, R.277
- Ligands: SOG.7
Ligand excluded by PLIPSOG.9: 5 residues within 4Å:- Chain A: F.196, V.263, L.264, F.268
- Ligands: SOG.30
Ligand excluded by PLIPSOG.10: 3 residues within 4Å:- Chain A: L.89, F.90, L.94
Ligand excluded by PLIPSOG.11: 5 residues within 4Å:- Chain A: K.96, Y.100, V.153, A.156, A.157
Ligand excluded by PLIPSOG.12: 5 residues within 4Å:- Chain A: F.215, W.219, M.245, L.249
- Ligands: PG4.5
Ligand excluded by PLIPSOG.13: 4 residues within 4Å:- Chain A: W.319, W.320, P.322, G.323
Ligand excluded by PLIPSOG.14: 3 residues within 4Å:- Chain A: R.181, W.182, A.183
Ligand excluded by PLIPSOG.15: 3 residues within 4Å:- Chain A: L.25, A.28, W.289
Ligand excluded by PLIPSOG.16: 7 residues within 4Å:- Chain A: A.31, V.32, V.35, C.254, A.293, A.296
- Ligands: SOG.17
Ligand excluded by PLIPSOG.17: 4 residues within 4Å:- Chain A: A.28, A.31, W.289
- Ligands: SOG.16
Ligand excluded by PLIPSOG.18: 4 residues within 4Å:- Chain A: L.66, V.69, L.70, I.74
Ligand excluded by PLIPSOG.19: 5 residues within 4Å:- Chain A: W.48, R.54, Y.59, V.62, L.138
Ligand excluded by PLIPSOG.20: 5 residues within 4Å:- Chain A: L.42, A.46, R.49, Q.312, W.320
Ligand excluded by PLIPSOG.21: 7 residues within 4Å:- Chain A: C.125, H.126, P.127, L.128, L.129, K.217
- Ligands: SOG.22
Ligand excluded by PLIPSOG.22: 4 residues within 4Å:- Chain A: H.126, Q.213
- Ligands: SOG.21, PGW.31
Ligand excluded by PLIPSOG.23: 6 residues within 4Å:- Chain A: D.5, R.9, W.12, E.278, A.279, A.282
Ligand excluded by PLIPSOG.24: 4 residues within 4Å:- Chain A: N.303, F.304, R.310, K.314
Ligand excluded by PLIPSOG.25: 7 residues within 4Å:- Chain A: G.39, P.299, N.303, F.304, F.313, F.317
- Ligands: SOG.26
Ligand excluded by PLIPSOG.26: 5 residues within 4Å:- Chain A: V.35, V.38, G.39, F.317
- Ligands: SOG.25
Ligand excluded by PLIPSOG.27: 4 residues within 4Å:- Chain A: L.186, I.190
- Ligands: SOG.28, SOG.29
Ligand excluded by PLIPSOG.28: 4 residues within 4Å:- Chain A: D.184, L.186, I.190
- Ligands: SOG.27
Ligand excluded by PLIPSOG.29: 2 residues within 4Å:- Ligands: SOG.6, SOG.27
Ligand excluded by PLIPSOG.30: 4 residues within 4Å:- Chain A: L.264, F.268
- Ligands: SOG.6, SOG.9
Ligand excluded by PLIP- 1 x PGW: (1R)-2-{[(S)-{[(2S)-2,3-dihydroxypropyl]oxy}(hydroxy)phosphoryl]oxy}-1-[(hexadecanoyloxy)methyl]ethyl (9Z)-octadec-9-enoate(Non-covalent)
- 1 x NA: SODIUM ION(Non-functional Binders)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Rappas, M. et al., Comparison of Orexin 1 and Orexin 2 Ligand Binding Modes Using X-ray Crystallography and Computational Analysis. J.Med.Chem. (2020)
- Release Date
- 2020-01-01
- Peptides
- Orexin receptor type 1: A
- SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
B - Membrane
-
We predict this structure to be a membrane protein.
- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 2.11 Å
- Oligo State
- monomer
- Ligands
- 1 x 7MA: N-ethyl-2-[(6-methoxypyridin-3-yl)-(2-methylphenyl)sulfonyl-amino]-N-(pyridin-3-ylmethyl)ethanamide(Non-covalent)
- 2 x SO4: SULFATE ION(Non-functional Binders)
- 2 x PG4: TETRAETHYLENE GLYCOL(Non-functional Binders)
- 25 x SOG: octyl 1-thio-beta-D-glucopyranoside(Non-covalent)(Non-functional Binders)
- 1 x PGW: (1R)-2-{[(S)-{[(2S)-2,3-dihydroxypropyl]oxy}(hydroxy)phosphoryl]oxy}-1-[(hexadecanoyloxy)methyl]ethyl (9Z)-octadec-9-enoate(Non-covalent)
- 1 x NA: SODIUM ION(Non-functional Binders)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Rappas, M. et al., Comparison of Orexin 1 and Orexin 2 Ligand Binding Modes Using X-ray Crystallography and Computational Analysis. J.Med.Chem. (2020)
- Release Date
- 2020-01-01
- Peptides
- Orexin receptor type 1: A
- SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
B - Membrane
-
We predict this structure to be a membrane protein.